Canadian Association of Gastroenterology – Canadian Institutes of Health Research – pharmaceutical partner* postdoctoral operating fellowship programme: An outstanding success that continues to excel!

Derek M McKay PhD¹, Sandra Daniels MSc²

1Intestinal Disease Research Programme, McMaster University, Hamilton, Ontario; 2Canadian Association of Gastroenterology National Office, Oakville, Ontario

Correspondence and reprints: Dr Derek M McKay, Intestinal Disease Research Programme, HSC-3N5C, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5. Telephone 905-525-9140 ext 22588, fax 905-522-3454, e-mail mckayd@mcmaster.ca

*Partners: Abbott Laboratories Ltd, ALTANA Pharma, AstraZeneca Canada Inc, Axcan Pharma Inc, Carsen Group Inc, Crohn’s and Colitis Foundation of Canada (CCFC), Ferring Pharmaceuticals, GlaxoSmithKline, Janssen-Ortho Inc, Novartis and Bristol Myers Squibb, Schering Canada Inc, Solvay Pharma Inc

Received for publication March 6, 2003. Accepted March 31, 2003

The Canadian Association of Gastroenterology (CAG) post-doctoral fellowship programme was initiated in 1992 with the goal of promoting excellence in Canadian gastroenterological research. With backing from multiple pharmaceutical partners and the Canadian Institutes of Health Research, 87 fellows were funded over the next ten years for a total investment of $8,730,101. Between 1992 and 2000, fellows authored 247 articles; 176 being original research articles, 31 (17.5%) of which appeared in journals with impact factors of greater than 10. As testament to the program’s success in developing young scientists, 31 former fellows (36%) have progressed to faculty positions. The fellowship programme continues to be an outstanding success and the flagship of CAG research activities.

Key Words: CAG; CIHR; Fellow training; Promoting research; Research investment; Research partners

A decade later, follow-up data have been collated on all but one of the fellows who have been supported by this fellowship programme. The synopsis of the data presented herein is testimony to the truly outstanding success of the fellowship programme. As current Chair of the CAG Research Committee, it is a privilege to be able to present the success of the fellowship programme to the CAG membership at large, and to acknowledge and thank CIHR and all of the partners that have supported, and continue to support, the training of talented post-doctoral fellows through the CAG Operating Fellowship Programme. Thank you!

Between 1992 and 2002, 87 research fellows have been supported with a total investment of $8,730,101 – $3,214,976 from CIHR and $5,515,125 from our partners (Figure 1). Figure 2 shows that approximately equal numbers of fellows authored original research articles in journals with impact factors greater than 10. As testament to the program’s success in developing young scientists, 31 former fellows (36%) have progressed to faculty positions. The fellowship programme continues to be a successful program and the flagship of CAG research activities.

Key Words: CAG; CIHR; Fellow training; Promoting research; Research investment; Research partners

In 1992, the Canadian Association of Gastroenterology (CAG) with support from pharmaceutical partners (initially Janssen-Ortho Inc then AstraZeneca Canada Inc) launched a post-doctoral fellowship programme with the central goals of promoting excellence in research in Canadian gastroenterology, hepatology and related disciplines, and broadening the research infrastructure in these areas across Canada. In 2000, in agreement with the Canadian Institutes of Health Research (CIHR: formerly the Medical Research Council of Canada), a 1:1 funding partnership was implemented with CIHR Research and Development and the growing list of CAG’s Partners (see acknowledgements). The aim was to maintain the CAG Operating Fellowship Programme as an innovative and effective means to nurture junior clinicians and PhD scientists with interests in intestinal health and disease processes.

A decade later, follow-up data have been collated on all but one of the fellows who have been supported by this fellowship programme. The synopsis of the data presented herein is testimony to the truly outstanding success of the fellowship programme. As current Chair of the CAG Research Committee, it is a privilege to be able to present the success of the fellowship programme to the CAG membership at large, and to acknowledge and thank CIHR and all of the partners that have supported, and continue to support, the training of talented post-doctoral fellows through the CAG Operating Fellowship Programme. Thank you!

Between 1992 and 2002, 87 research fellows have been supported with a total investment of $8,730,101 – $3,214,976 from CIHR and $5,515,125 from our partners (Figure 1). Figure 2 shows that approximately equal num-
bers of MD and PhD fellows were successful in achieving funding, with the lower panel illustrating the distribution of the fellowships by institution. The concentration at the University of Calgary, University of Toronto and McMaster University reflects the greater number of applications from these institutions, which in turn is likely a consequence of the greater number of faculty active in gastroenterological research at these sites.

With such impressive investment in the fellowship programme, one must ask whether this investment has enhanced Canadian research in gastroenterology and related disciplines. The unequivocal and resounding answer is yes. Of the 87 individuals funded, 31 (36%) now hold faculty positions and two-thirds of these are at Canadian institutions. Moreover, of those fellows who have secured a faculty position, 14 (42%) hold PhDs, 14 (42%) hold MDs and three (16%) hold both MD and PhD degrees. Figure 3 shows the status of the remaining 56 (64%) fellows who received support through this CAG programme, and it is noteworthy that 44% of all fellows are currently conducting post-doctoral research fellowships. Not only have 36% of the fellowship awardees secured faculty positions, some – such as Drs N Jones (University of Toronto), K Madsen (University of Alberta) and N Vergnolle (University of Calgary) – have, in turn, become supervisors of programme-funded fellows. Others, such as Drs N Abraham (Dalhousie University), D Armstrong (McMaster University), K Jacobson (University of British Columbia) and J Marshall (McMaster University) are members of CAG committees, with the opportunity to contribute to the continued success of not only the research fellowship programme, but the CAG in general.

An often used index of scientific success is publication rate and publication quality. CAG fellows have performed admirably on both counts (Figure 4). The funded fellows (1992 to 2000) have been first or contributing author on 247 publications, 176 of which are original research articles: 139 of these appeared in 65 different citation-impact indexed journals (it is noteworthy that these numbers underestimate the productivity of fellows since they span the period 1992 to 2000, whereas the funding information presented herein is for 1992 to 2002). Add to this approximately 320 published abstracts (and concomitant presentations at national and international conferences) and it is clear that the fellows have been prolific. But what of the quality of these publications? Using the citation impact factor as an indicator of publication quality, 31 (17.5%) of the original research papers have appeared in journals with impact factors greater than 10. This is a remarkable achievement for any subspecialty group. Moreover, 33 papers (19%) were published in The American Journal of Physiology (impact factor approximately 3.8) or Gastroenterology (impact factor approximately 13.1), the two major journals for gastrointestinal research papers.
There is another less tangible, but no less important, impact of the CAG Operating Fellowship Programme. The CAG fellows have been tremendous assets to the laboratories they joined, independent of whether their supervisor was an experienced mainstay of the CAG or at the assistant professor level. While difficult to formally assess, the additional critical mass and infrastructure created by the CAG Operating Fellowship Programme aided junior faculty as they established their independent research laboratories, provided support and research resources for more senior investigators, and undoubtedly bolstered the international impact of Canadian gastroenterological research.

In essence, what began as a fledgling innovative idea – the CAG Operating Fellowship – has matured into an outstanding success, and is now the flagship program of CAG research activities. Eighteen new fellowships and two fellow-to-faculty awards (a new program to bridge talented fellows with two to four years postdoctoral training into full-time faculty positions), effective July 2003, were presented at an awards ceremony held at the CAG-Canadian Digestive Diseases Week Conference (February 24, 2003) and this bodes well for meeting one of the major mandates of the CAG: to build, in collaboration with CIHR and our Partners, Canadian capacity and expertise in the discipline of gastroenterology and nutrition, and to promote excellence in research. Laudable progress has been made and we must now strive to sustain the momentum that has been generated in the CAG Operating Fellowship Programme and create complementary means to highlight the value of, and need for, continued investment in gastroenterological research in Canada.

Finally, on behalf of the Canadian Association of Gastroenterology, I would reiterate our appreciation and sincere thanks to CIHR and all of the Partners for their longstanding support of the CAG Operating Fellowship Programme. All parties involved with this program, both sponsors and researchers, are to be congratulated.

ACKNOWLEDGEMENTS: Comments by Drs PM Sherman (President, CAG) and D Leddin (President Elect, CAG) and Mr P Sinclair (National Executive Director, CAG) are gratefully acknowledged. Financial support for the operating fellowships provided by Canadian Institutes of Health Research (CIHR) and the CAG partners (Abbott Laboratories Ltd, AstraZeneca Canada Inc, Axcan Pharma Inc, Carsen Group Inc, Crohn's and Colitis Foundation of Canada (CCFC), Ferring Pharmaceuticals, GlaxoSmithKline, Janssen-Ortho Inc, Novartis and Bristol Myers Squibb, Schering Canada Inc, and Solvay Pharma Inc) is greatly appreciated.